TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 70149
Drug: Corticotrophin (maintenance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticotrophin (maintenance dose 1 mg/week, i.m.)
Study: 31544345
Drug: Intensive Behavioral
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive Behavioral Therapy (IBT) protocol
Study: 28623944
Drug: Manual therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual therapy (MT) that includes spinal manipulative therapy (SMT) plus standardised exercise program
Study: 23414061
Drug: Mesalazine 1000
Normalized name: mesalazine 1000 MG Rectal Foam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mesalazine 1000 mg three times daily
Study: 21675064
Drug: Sedation with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sedation with propofol infusion (10 to 20 mg x hour), n = 20
Study: 19368793
Drug: 4microg Trivalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4microg Trivalent influenza DNA vaccine
Study: 19368793
Drug: 2microg Trivalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2microg Trivalent influenza DNA vaccine plus DEI‐LT
Study: 16940406
Drug: Orlistat 60
Normalized name: orlistat 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orlistat 60 mg, given 3 times daily
Study: 8100044
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg modafinil b.i.d.
Study: 23774725
Drug: Neurofeedback combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neurofeedback combined with conventional treatment
Study: 20221770
Drug: Pregabalin (PGB)
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pregabalin (PGB) as mono- or add-on therapy, flexible-dosage, administered twice daily
Study: 20221770
Drug: Non-Pregabalin therapy
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Non-Pregabalin therapy (change established doses and combinations of pre-existing mono- or combination therapy)
Study: 18677810
Drug: Fengweicao Granule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fengweicao Granule (FWCG), 5 g orally twice a day for 3 months
Study: 18677810
Drug: Proscar, 5
Normalized name: Proscar, 5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proscar, 5 mg per day for 3 months
Study: 16911387
Drug: Calcipotriol/betamethasone dipropionate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcipotriol/betamethasone dipropionate ointment (Daivobet/Dovobet)
Study: 12930031
Drug: Patient counseling
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient counseling on drug, diseases, and lifestyle modification from a pharmacist after a hospital visit.
Study: 23542898
Drug: Human apoC‐III
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human apoC‐III antisense drug
Study: 16641119
Drug: Snus (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Snus (oral moist snuff) consumption (n = 21) in ex-smokers
Study: 11718043
Drug: Inappropriate initial
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Inappropriate initial empirical antibiotic treatment
Study: 9254255
Drug: Liposomes with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liposomes with antibiotics and ectericide
Study: 8129908
Drug: One type
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: One type of vaccine
Study: 28720395
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of ACZ and NAC
Study: 23237605
Drug: 0.01 mg.kg(‐1)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.01 mg.kg(‐1) penehyclidine hydrochloride
Study: 16369129
Drug: Granulocyte colony-stimulating
Normalized name: Granulocyte colony-stimulating factor lenograstim
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granulocyte colony-stimulating factor (G-CSF) 1 x 300 or 480 microg s.c. prior to standard antibiotic treatment
Study: 23445173
Drug: 2BOD (ball
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2BOD (ball attachment on two implants)
Study: 23445173
Drug: 2ROD (bar
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2ROD (bar attachment on two implants)
Study: 23445173
Drug: 4ROD (bar
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4ROD (bar attachments on four implants)
Study: 23328326
Drug: Hypnosis (hypnotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypnosis (hypnotic analgesia suggestions)
Study: 20492050
Drug: Preferred music
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preferred music listening intervention (30-minute sessions, twice a week for six weeks)
Study: 8150115
Drug: Gonadotropin-releasing hormone
Normalized name: Gonadotropin-releasing hormone
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gonadotropin-releasing hormone agonist (GnRH‐a) discontinued as gonadotropin stimulation began
Study: 8150115
Drug: Gonadotropin-releasing hormone
Normalized name: Gonadotropin-releasing hormone
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gonadotropin-releasing hormone agonist (GnRH‐a) continued as gonadotropin stimulation began
Study: 29876530
Drug: (Pyr(1))apelin‐13 infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: (Pyr(1))apelin‐13 infusion
Study: 29876530
Drug: (Pyr(1))apelin‐13 infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: (Pyr(1))apelin‐13 infusion with concomitant phosphodiesterase type 5 inhibition
Study: 22982658
Drug: Sorafenib (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sorafenib (400 mg orally twice daily for 2 months)
Study: 20012601
Drug: Control (verapamil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (verapamil 60 mg without lovastatin)
Study: 17413685
Drug: Control PI
Normalized name: Pepto Diarrhea Control Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control PI drug(s) (CPI)
Study: 16319551
Drug: Red grape
Normalized name: CVS Children's Cold & Cough Elixir (Red Grape)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Red grape polyphenol extract (600 mg)
Study: 16319551
Drug: Placebo (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (20 ml of water)
Study: 8568486
Drug: Formalin‐inactivated, alum‐adjuvanted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formalin‐inactivated, alum‐adjuvanted hepatitis A vaccine (25 units, MSD) at 0, 24 weeks (group I)
Study: 8568486
Drug: Formalin‐inactivated, alum‐adjuvanted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formalin‐inactivated, alum‐adjuvanted hepatitis A vaccine (25 units, MSD) at 0, 2, 24 weeks (group II)
Study: 2007359
Drug: Misoprostol 300
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Misoprostol 300 micrograms four times daily
Study: 6284190
Drug: Misonidazole (MISO)
Normalized name: Metronidazole
DrugBank: Misonidazole (DB11716)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Misonidazole (MISO) at 0.15 g/m2
Study: 6284190
Drug: Misonidazole (MISO)
Normalized name: Metronidazole
DrugBank: Misonidazole (DB11716)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Misonidazole (MISO) at 0.30 g/m2
Study: 6284190
Drug: Misonidazole (MISO)
Normalized name: Metronidazole
DrugBank: Misonidazole (DB11716)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Misonidazole (MISO) at 0.45 g/m2
Study: 8906943
Drug: Nimodipine (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nimodipine (1.5 to 2.0 mg/kg/day) administered orally or as continuous intravenous drip for the first three days followed by oral therapy along with standard treatment.
Study: 2319049
Drug: Self-guided behavioral
Normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-guided behavioral treatment (self-selected modules, randomly administered modules, no modules)
Study: 508553
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of metoclopramide (5 and 10 mg)
Study: 508553
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of metoclopramide (aqueous solution)
Study: 508553
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of metoclopramide (slow release tablet)
Study: 31679512
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care physiotherapy treatment
Study: 18945396
Drug: Pharmacologic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacologic treatment (SSRIs)
Study: 18945396
Drug: Pharmacologic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacologic treatment (other antidepressants)
Study: 14650863
Drug: Fondaparinux for
Normalized name: Fondaparinux
DrugBank: Fondaparinux (DB00569)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fondaparinux for treatment of VTE (MATISSE DVT and MATISSE PE)
Study: 14650863
Drug: Fondaparinux for
Normalized name: Fondaparinux
DrugBank: Fondaparinux (DB00569)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fondaparinux for treatment of acute coronary syndromes (PENTALYSE and PENTUA)
Study: 10818057
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment (chlorthalidone-based treatment)
Study: 10818057
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment with hypokalemia
Study: 10818057
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment with normal potassium levels
Study: 8788488
Drug: Pindolol pre-treatment
Normalized name: Pindolol
DrugBank: Pindolol (DB00960)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pindolol pre-treatment
Study: 1521944
Drug: Captopril (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (50 mg/24 h)
Study: 6442971
Drug: BCG and
Normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCG and 5‐fluorouracil in combination with hydroxyurea, methyl‐CCNU and mitomycin C (regimen B)
Study: 29484469
Drug: 8-day antibiotic
Normalized name: Antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8-day antibiotic therapy
Study: 29484469
Drug: 15-day antibiotic
Normalized name: Antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15-day antibiotic therapy
Study: 22922781
Drug: Treatment for
Normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment for symptomatic convergence insufficiency
Study: 11432682
Drug: Ceftriaxone (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone (2 g) as a single intravenous dose at anesthetic induction
Study: 11432682
Drug: Cefazolin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefazolin (1 g) plus clindamycin (0.6 g) administered intravenously at anesthetic induction and for two more doses at 8‐hourly intervals for a total of 3 days
Study: 8407423
Drug: Single agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single agent cisplatin and radiotherapy
Study: 2439827
Drug: bopindolol (1-2
Approvals — FDA: no, EMA: no, PMDA: no
Description: bopindolol (1-2 mg daily)
Study: 2439827
Drug: atenolol (50-100
Approvals — FDA: no, EMA: no, PMDA: no
Description: atenolol (50-100 mg daily)
Study: 30608598
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy using gemcitabine and S-1
Study: 28964662
Drug: Levothyroxine (LT-4)
Normalized name: LT KIT
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Levothyroxine (LT-4) replacement therapy for 2 months
Study: 23195006
Drug: CNI-free maintenance
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: CNI-free maintenance therapy
Study: 23195006
Drug: Low-dose CNI
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose CNI therapy
Study: 9530599
Drug: Irrigating solution
Normalized name: IRRIGATING SOLUTIONS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irrigating solution with heparin-sodium (10 IU/mL)
Study: 9530599
Drug: Regular irrigating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular irrigating solution (control)
Study: 30913208
Drug: Aspirin (100mg/d)
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin (100mg/d)
Study: 30913208
Drug: Placebo (for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (for both fish oil and aspirin)
Study: 26341548
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of 400 μg salbutamol in standard posture
Study: 26341548
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of 200 μg salbutamol in standard posture
Study: 26341548
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of salbutamol in forward leaning posture
Study: 20713345
Drug: Biphasic insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Biphasic insulin aspart 70/30 (BIAsp 30) + metformin
Study: 20713345
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine + metformin + secretagogues
Study: 14733417
Drug: Intravenous ascorbic
Normalized name: ascorbate
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ascorbic acid (AA) 200 mg 3 times/week
Study: 14733417
Drug: Low-dose desferroxamine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose desferroxamine (DFO) 1 mg/Kg/week
Study: 9168506
Drug: Intensive three-step
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive three-step protocol consisting of colistin inhalations and oral ciprofloxacin.
Study: 9168506
Drug: Aggressive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aggressive treatment (intensive protocol).
Study: 9168506
Drug: High-dose treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose treatment with colistin inhalation and oral ciprofloxacin for 3 months.
Study: 3541428
Drug: Purified chick
Normalized name: rabies vaccine, purified chick embryo cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: Purified chick embryo cell vaccine
Study: 3541428
Drug: Purified Vero
Normalized name: RAYON,PURIFIED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Purified Vero rabies vaccine
Study: 3541428
Drug: Fetal bovine
Normalized name: Fetal Bovine Serum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fetal bovine kidney cell vaccine
Study: 3541428
Drug: HDCV (commercial
Approvals — FDA: no, EMA: no, PMDA: no
Description: HDCV (commercial human diploid cell vaccine)
Study: 3541428
Drug: 2-1-1 postexposure
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-1-1 postexposure regimen (all vaccines)
Study: 28439774
Drug: High-dose intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose intravenous (IV) albumin infusion (n=100)
Study: 28439774
Drug: High-dose intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose intravenous (IV) albumin infusion within 2 hours of onset
Study: 21716593
Drug: D-003 (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-003 (10 mg/day)
Study: 12562581
Drug: Tandospirone (5-HT(1A)
Normalized name: 5-HT
DrugBank: Tandospirone (DB12833)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tandospirone (5-HT(1A) agonist)
Study: 10357321
Drug: Intravenous magnesium
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous magnesium (5.4 mmol)
Study: 1756347
Drug: Anti-anxiety drug
Normalized name: INVESTIGATIONAL ANTI-ANXIETY DRUGS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-anxiety drug
Study: 26475420
Drug: Intravenous dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous dexamethasone (DEX) 5 mg/d
Study: 26475420
Drug: Placebo therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo therapy (intravenous normal saline)
Study: 26475420
Drug: Both DEX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both DEX and placebo treatments
Study: 16761235
Drug: Topical ofloxacin
Normalized name: Ofloxacin
DrugBank: Ofloxacin (DB01165)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical ofloxacin (0.3%) four times a day for 3 days
Study: 16761235
Drug: Topical ofloxacin
Normalized name: Ofloxacin
DrugBank: Ofloxacin (DB01165)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical ofloxacin (0.3%)
Study: 15101564
Drug: Ziprasidone i.m.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ziprasidone i.m. 5 mg qid
Study: 15101564
Drug: Ziprasidone i.m.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ziprasidone i.m. 10 mg qid
Study: 15101564
Drug: Ziprasidone i.m.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ziprasidone i.m. 20 mg qid
Study: 15101564
Drug: Haloperidol i.m.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol i.m. up to 10 mg bid-qid
Study: 15101564
Drug: Transition to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transition to oral ziprasidone
Study: 9845401
Drug: Ranitidine bismuth
Normalized name: RANITIDINE BISMUTH CITRATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine bismuth citrate 400 mg b.d. and clarithromycin 500 mg b.d. for 2 weeks (RC)
Study: 9845401
Drug: Ranitidine bismuth
Normalized name: RANITIDINE BISMUTH CITRATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine bismuth citrate 400 mg b.d., clarithromycin 500 mg b.d. and metronidazole 400 mg b.d. for 1 week (RCM)
Study: 2808259
Drug: More extensive
Normalized name: polyurethane-35 (not more than MPA.S at 40 %)
Approvals — FDA: no, EMA: no, PMDA: no
Description: More extensive treatment experimental group
Study: 2808259
Drug: Minimal treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minimal treatment control group
Study: 1108582
Drug: etidocaine 1.0%
Approvals — FDA: no, EMA: no, PMDA: no
Description: etidocaine 1.0% with adrenaline 5 mug/ml
Study: 26880476
Drug: Internet-based Climate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based Climate Schools: Ecstasy and Emerging Drugs module delivered once weekly for 4 weeks during health education classes.
Study: 26880476
Drug: Internet-based Climate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based Climate Schools: Ecstasy and Emerging Drugs module.
Study: 11783328
Drug: XMT plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: XMT plus western medicine
Study: 3514366
Drug: Intravaginal application
Normalized name: taurolidine
DrugBank: Taurolidine (DB12473)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravaginal application of tablets containing PGE2
Study: 17540227
Drug: Behavioral inpatient
Normalized name: Impatiens irvingii whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral inpatient treatment
Study: 17540227
Drug: Psychodynamic inpatient
Normalized name: Impatiens irvingii whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychodynamic inpatient treatment
Study: 17540227
Drug: Overall treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall treatment (both types)
Study: 15040538
Drug: 4 mg/day
Normalized name: Neupro 4 MG/Day 24 HR Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg/day of recombinant human growth hormone (rhGH) for 12 weeks
Study: 15040538
Drug: Placebo, alternate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, alternate day or twice weekly dosing of rhGH
Study: 3630804
Drug: Maintenance condition
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance condition (includes behavioral contracting and extended treatment)
Study: 31285069
Drug: Daily exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily exercise program for 30 days, once a day for 7-10 minutes.
Study: 23419385
Drug: Midodrine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midodrine plus standard medical therapy (SMT)
Study: 23419385
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of midodrine and clonidine plus SMT
Study: 21627522
Drug: Methadone IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methadone IV (0.3 mg/kg)
Study: 21627522
Drug: Methadone OTM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methadone OTM (0.6 mg/kg)
Study: 15041578
Drug: 0.8 mL/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.8 mL/kg of plain local anesthetic mixture (lidocaine 1% + bupivacaine 0.25% (50/50) + 1 microg/mL of fentanyl)
Study: 15041578
Drug: 1 mL/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mL/kg of the same mixture with 5 microg/mL of adrenaline
Study: 11348933
Drug: Short-acting beta(2)-agonist
Normalized name: Short-acting sulfonamides
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short-acting beta(2)-agonist (SA), n = 48
Study: 11348933
Drug: Long-acting beta(2)-agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-acting beta(2)-agonist (LA), n = 50
Study: 9554298
Drug: Topical cyproterone
Normalized name: cyproterone
DrugBank: Cyproterone acetate (DB04839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical cyproterone acetate lotion (20 mg)
Study: 9554298
Drug: Oral cyproterone
Normalized name: cyproterone
DrugBank: Cyproterone acetate (DB04839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cyproterone acetate (2 mg) and ethinyl estradiol (0.035 mg)
Study: 29961572
Drug: Tocilizumab (280
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tocilizumab (280 mg intravenous infusion)
Study: 28801444
Drug: Intravesical maintenance
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravesical maintenance BCG (mBCG) immunotherapy
Study: 21576829
Drug: Valsartan (40-80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan (40-80 mg)
Study: 15385012
Drug: 1.25 mg
Normalized name: menthol 1.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.25 mg x kg(‐1) 0.5% levobupivacaine
Study: 15385012
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg x kg(‐1) levobupivacaine